Table 5.
Blood pressure before and after treatment, and the incidence of adverse events in acute cerebral infarction patients between the glycoside and ignotin (CEGI) and placebo groups
| CEGI group (n = 236) | Placebo group (n = 79) | Statistics | P-value | |
|---|---|---|---|---|
| Systolic blood pressure (mmHg) | ||||
| Before treatment | 146±20.8 | 147.3±23.2 | t=–0.29 | 0.768 |
| On days 90 after treatment | 138.2±14.7 | 137.7±13.8 | t=0.27 | 0.787 |
| Change | –8.39±15.4 | –8.74±15.3 | t=0.17 | 0.862 |
| P-value | < 0.05 | |||
| Diastolic blood pressure (mmHg) | ||||
| Before treatment | 86.6±13 | 84.9±12.1 | t=1.02 | 0.31 |
| On days 90 after treatment | 81.8±9.3 | 81.1±9.0 | t=0.63 | 0.528 |
| Change | –4.86±11.7 | –3.49±10.2 | t=–0.93 | 0.354 |
| P-value | < 0.05 | |||
| Adverse event [n (%)] | ||||
| All adverse events | 98 (41.5) | 29 (36.7) | F=0.51 | > 0.05 |
| Serious adverse event | 2 (0.85) | 1 (1.27) | ||
| Drug-related adverse events | 0 | 0 | F=1.0000 | |
| Drug-unrelated adverse events | 98 (41.5) | 29 (36.7) | ||
| Adverse events leading to the suspension of the study | 0 | 0 |
Data are expressed as the mean ± SD, except adverse events. The paired t-test was used to test differences in blood pressure between before and after treatment in both groups, and Fisher’s exact test was used to test differences in adverse events between the CEGI and placebo groups.